CO2018000196A2 - Agente terapéutico para tratar el síndrome de hunter y método de tratamiento - Google Patents
Agente terapéutico para tratar el síndrome de hunter y método de tratamientoInfo
- Publication number
- CO2018000196A2 CO2018000196A2 CONC2018/0000196A CO2018000196A CO2018000196A2 CO 2018000196 A2 CO2018000196 A2 CO 2018000196A2 CO 2018000196 A CO2018000196 A CO 2018000196A CO 2018000196 A2 CO2018000196 A2 CO 2018000196A2
- Authority
- CO
- Colombia
- Prior art keywords
- week
- injection
- once
- hunter syndrome
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un agente terapéutico del síndrome de Hunter y, más específicamente, a un agente terapéutico del síndrome de Hunter que puede reducir el número de visitas al hospital de pacientes con síndrome de Hunter a dos veces al mes o menos, al contener una primera composición para inyectarse por vía intravenosa y una segunda composición para inyectarse por vía subcutánea, que presenta un efecto medicinal equivalente o mayor al de una inyección por vía intravenosa convencional una vez a la semana, los pacientes aumentan el cumplimiento de la toma de medicamentos en comparación con los agentes terapéuticos y los métodos de tratamiento convencionales, y permite un mayor bienestar y conveniencia para el paciente. De acuerdo con la presente invención, el método de co-inyección por vía IV/SC muestra un efecto terapéutico equivalente o superior comparado con el de una inyección por vía IV convencional una vez a la semana, mientras que permite a un paciente visitar el hospital con una frecuencia menor que una vez a la semana, como en visitas convencionales, reemplazando el método convencional de inyección por vía IV una vez a la semana, que requiere que el paciente visite el hospital una vez a la semana, por inyecciones por vía SC mediante las cuales un cuidador del paciente puede realizar directamente en casa una cantidad predeterminada de inyecciones por vía intravenosa. Esto va en contra de un concepto convencional de que el efecto terapéutico logrado por una inyección por vía SC no sería superior al efecto terapéutico logrado por una inyección por vía IV. Por lo tanto, la presente invención se refiere a un agente terapéutico y a un método de tratamiento del cual mejora espectacularmente un efecto del tratamiento del síndrome de Hunter con respecto al de una tecnología convencional.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187867P | 2015-07-02 | 2015-07-02 | |
| KR1020150187297A KR20170004814A (ko) | 2015-07-02 | 2015-12-28 | 헌터증후군 치료제 |
| PCT/KR2016/007203 WO2017003270A1 (ko) | 2015-07-02 | 2016-07-04 | 헌터증후군 치료제 및 치료방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018000196A2 true CO2018000196A2 (es) | 2018-03-28 |
Family
ID=57833331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0000196A CO2018000196A2 (es) | 2015-07-02 | 2018-01-11 | Agente terapéutico para tratar el síndrome de hunter y método de tratamiento |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10561713B2 (es) |
| EP (1) | EP3318267B1 (es) |
| JP (2) | JP6606199B2 (es) |
| KR (3) | KR20170004814A (es) |
| CN (1) | CN107921091A (es) |
| BR (1) | BR112018000051A2 (es) |
| CA (1) | CA2990370C (es) |
| CL (1) | CL2018000002A1 (es) |
| CO (1) | CO2018000196A2 (es) |
| EA (1) | EA038110B1 (es) |
| ES (1) | ES2866957T3 (es) |
| HK (1) | HK1252663A1 (es) |
| MX (1) | MX2017016302A (es) |
| PE (1) | PE20190351A1 (es) |
| PL (1) | PL3318267T3 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2930749T3 (es) | 2015-07-02 | 2022-12-21 | Hoffmann La Roche | Lactamas bicíclicas como inhibidores de la proteína de interacción con el receptor 1 (RIP1) cinasa para tratar, por ejemplo, enfermedades inflamatorias |
| CN109843886B (zh) | 2016-10-17 | 2022-04-19 | 豪夫迈·罗氏有限公司 | 二环吡啶酮内酰胺及其使用方法 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3692070A1 (en) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| CN112074519A (zh) | 2018-04-20 | 2020-12-11 | 豪夫迈·罗氏有限公司 | 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物 |
| KR102671857B1 (ko) | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
| US20210393618A1 (en) * | 2018-10-11 | 2021-12-23 | Indivior Uk Limited | Buprenorphine to treat respiratory depression |
| CN112805026A (zh) * | 2019-02-06 | 2021-05-14 | 桑格摩生物治疗股份有限公司 | 用于治疗i型黏多糖贮积症的方法 |
| JP2023529686A (ja) | 2020-06-16 | 2023-07-11 | ノベルファーマ株式会社 | グルタル酸尿症治療用組成物及びこの投与方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1006443B1 (pt) | 2009-04-22 | 2021-05-25 | Alteogen, Inc | Proteína ou peptídeo de fusão e método para aumentar a meia-vida in vivo de uma proteína ou peptídeo |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| IL291554B2 (en) * | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Administering therapeutic agents to the central nervous system |
| JP6045492B2 (ja) * | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| ES2728447T3 (es) | 2011-12-23 | 2019-10-24 | Shire Human Genetic Therapies | Tratamiento del déficit cognitivo del síndrome de Hunter para la administración intratecal de iduronato-2-sulfatasa |
| CA2868466A1 (en) * | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate-2-sulfatase |
| JP2015013624A (ja) * | 2013-07-08 | 2015-01-22 | 船井電機株式会社 | 手動推進器具 |
-
2015
- 2015-12-28 KR KR1020150187297A patent/KR20170004814A/ko not_active Application Discontinuation
-
2016
- 2016-07-04 KR KR1020197036839A patent/KR102213055B1/ko active IP Right Grant
- 2016-07-04 BR BR112018000051-5A patent/BR112018000051A2/pt active Search and Examination
- 2016-07-04 MX MX2017016302A patent/MX2017016302A/es unknown
- 2016-07-04 PL PL16818303T patent/PL3318267T3/pl unknown
- 2016-07-04 JP JP2017568199A patent/JP6606199B2/ja active Active
- 2016-07-04 PE PE2017002893A patent/PE20190351A1/es unknown
- 2016-07-04 EA EA201890182A patent/EA038110B1/ru unknown
- 2016-07-04 KR KR1020187001448A patent/KR20180015256A/ko active Search and Examination
- 2016-07-04 US US15/738,017 patent/US10561713B2/en active Active
- 2016-07-04 CN CN201680038666.3A patent/CN107921091A/zh active Pending
- 2016-07-04 CA CA2990370A patent/CA2990370C/en active Active
- 2016-07-04 EP EP16818303.6A patent/EP3318267B1/en active Active
- 2016-07-04 ES ES16818303T patent/ES2866957T3/es active Active
-
2018
- 2018-01-02 CL CL2018000002A patent/CL2018000002A1/es unknown
- 2018-01-11 CO CONC2018/0000196A patent/CO2018000196A2/es unknown
- 2018-09-18 HK HK18111970.1A patent/HK1252663A1/zh unknown
-
2019
- 2019-09-05 JP JP2019161855A patent/JP6858231B2/ja active Active
- 2019-11-27 US US16/698,403 patent/US20200093899A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1252663A1 (zh) | 2019-05-31 |
| ES2866957T3 (es) | 2021-10-20 |
| PL3318267T3 (pl) | 2021-07-12 |
| JP6606199B2 (ja) | 2019-11-13 |
| US20180303914A1 (en) | 2018-10-25 |
| BR112018000051A2 (pt) | 2018-09-04 |
| EP3318267B1 (en) | 2021-02-24 |
| EA038110B1 (ru) | 2021-07-07 |
| CA2990370C (en) | 2022-05-17 |
| CA2990370A1 (en) | 2017-01-05 |
| KR20180015256A (ko) | 2018-02-12 |
| EP3318267A1 (en) | 2018-05-09 |
| CL2018000002A1 (es) | 2018-06-29 |
| EA201890182A1 (ru) | 2018-06-29 |
| US20200093899A1 (en) | 2020-03-26 |
| KR20190141026A (ko) | 2019-12-20 |
| EP3318267A4 (en) | 2019-02-27 |
| JP6858231B2 (ja) | 2021-04-14 |
| JP2020019775A (ja) | 2020-02-06 |
| KR102213055B1 (ko) | 2021-02-08 |
| JP2018519326A (ja) | 2018-07-19 |
| US10561713B2 (en) | 2020-02-18 |
| PE20190351A1 (es) | 2019-03-07 |
| MX2017016302A (es) | 2018-03-23 |
| CN107921091A (zh) | 2018-04-17 |
| KR20170004814A (ko) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018000196A2 (es) | Agente terapéutico para tratar el síndrome de hunter y método de tratamiento | |
| MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
| BR112018016001A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| BR112017021311A2 (pt) | composições farmacêuticas para terapia de combinação | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| BR112015023007A8 (pt) | dispositivo de injeção de múltiplas câmaras | |
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
| BR112016028177A2 (pt) | seringa | |
| BR112013010345A2 (pt) | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| RU2012123182A (ru) | Способ коррекции психического состояния пациентов и антиоксидантого статуса при органическом расстройстве личности | |
| Bordbar et al. | The challenge of chemotherapy extravasations | |
| BR112022004723A2 (pt) | Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração | |
| EA201700347A3 (ru) | Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения |